Biocon Biologics, which has said it will acquire the biosimilars business of Viatris Inc for $3.335 billion, will file for an initial public offering (IPO) in 18-24 months, executive chairperson Kiran Mazumdar-Shaw told CNBC-TV18 on February 28.
Biocon is well positioned to tap the biosimilar opportunity globally. With this deal Biocon Biologics is scripting a new chapter, she added.
"Aflibercept injection is a part of this deal and we have the option to buy it by FY25," Shaw said.
"Built the biosimilar business in the last few years, and the intent is to make it more affordable. Biosimilar offers a global opportunity. 58 percent of biosimilars approved in the European Union were between 2017 and 2019. The trend of uptick in biosimilars is expected to continue for the next 10 years," she added.